Are peptides legal in the United States?
Sourced guide to the legal status of peptides in the United States, refreshed automatically from live research.
Overall Status: Restricted
Short answer: Peptides are restricted in the United States: FDA-approved peptide drugs (e.g., semaglutide, tirzepatide, somatropin/HGH) are legal only by prescription, while unapproved research peptides like BPC-157 and TB-500 cannot lawfully be sold, compounded, or marketed for human use.
Important: This information is for educational purposes only and does not constitute legal advice. Laws and enforcement policies change. Consult a qualified attorney for specific legal guidance.
Overview
Peptides are restricted in the United States under a two-track system enforced by the Food and Drug Administration (FDA): peptides with FDA-approved drug applications are legal but prescription-only, while peptides never approved as drugs — such as BPC-157 and TB-500 — are treated as unapproved new drugs that cannot be sold for human consumption, regardless of 'research use only' labeling. Compounding pharmacies are separately restricted to using only bulk substances on FDA's approved 503A/503B lists, USP-monograph substances, or components of FDA-approved drugs, which has led FDA to exclude several popular peptides (including proposals to remove semaglutide, tirzepatide, and liraglutide) from lawful compounding. There is no dedicated federal 'peptide schedule' — the framework is drug-approval and compounding law, not DEA controlled-substance scheduling, for most of these compounds.
Key Points
- The FDA treats BPC-157 as an unapproved bulk drug substance that it is actively evaluating and has not placed on the 503A compounding bulks list, meaning licensed pharmacies generally cannot lawfully compound it for human use in the United States. [1]
- Under FDA's interim policy, licensed compounding pharmacies in the United States may only use a bulk drug substance if it appears on the FDA's 503A bulks list, complies with an applicable USP or National Formulary monograph, or is a component of an FDA-approved drug. [3]
- The FDA has proposed to formally exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list, finding no clinical need for outsourcing facilities to compound these drugs from bulk substances now that FDA-approved brand versions are available. [5]
- Peptide vendors in the United States that label products 'for research use only, not for human consumption' are not exempt from the Federal Food, Drug, and Cosmetic Act, as stated in FDA warning letters sent to such vendors. [9]
- Popular unapproved peptides marketed online in the United States — including BPC-157, TB-500, Thymosin alpha-1, CJC-1295, and Ipamorelin — are currently barred from lawful pharmacy compounding under FDA's 503A/503B framework. [8]
- No FDA or DEA source was found during this research confirming a specific personal-importation exemption for research peptides such as BPC-157 or TB-500 for individual travelers, so this point reflects a gap rather than a confirmed rule. (No reliable source found for this point -- flagged as unverified rather than stated as fact.)
Peptide-by-peptide status in United States
| BPC-157 | BPC-157 is not an FDA-approved drug in the United States and remains under FDA evaluation as a nominated bulk drug substance, meaning it is not lawful for a pharmacy to compound or sell it for human use. [1] |
|---|
| Semaglutide / Tirzepatide (GLP-1 weight-loss and diabetes drugs) | Semaglutide and tirzepatide are FDA-approved, prescription-only drugs in the United States (as Ozempic/Wegovy and Mounjaro/Zepbound), but the FDA has proposed barring outsourcing facilities from compounding them from bulk substances now that approved products are available. [5] |
|---|
| TB-500 | TB-500 has not been approved by the FDA for any medical indication in the United States and is considered a research chemical or unapproved drug that is not permitted for human consumption. [7] |
|---|
| Human Growth Hormone (HGH/Somatropin) | No source was retrieved during this research confirming the specific federal criminal-distribution rule for HGH in the United States, so its prescription-only, FDA-approved status here reflects general regulatory context rather than a directly cited source in this record. |
|---|
Last researched: 2026-09-10
Frequently asked questions
No — in the United States, BPC-157 is not FDA-approved and cannot be lawfully sold for human use even when labeled 'research use only,' since FDA warning letters state that such labeling does not exempt sellers from the Federal Food, Drug, and Cosmetic Act.
[9]
Compounded semaglutide and tirzepatide have existed in a narrowing legal window in the United States, and the FDA has proposed to exclude these substances from the 503B bulks list entirely, which would end lawful bulk compounding of them by outsourcing facilities.
[5]
No confirmed source was found in this research showing that TB-500 is scheduled as a DEA-controlled substance in the United States; rather, it is treated as an unapproved drug not permitted for human use, which is a distinct legal category from DEA scheduling.
[7]
This research did not locate a specific FDA or customs source confirming a personal-import exemption for unapproved research peptides such as BPC-157 or TB-500, so travelers should treat this as an open question rather than a confirmed allowance.
As of the sources reviewed, peptides including BPC-157, TB-500 (thymosin beta-4 fragment), Thymosin alpha-1, CJC-1295, and Ipamorelin are currently barred from lawful pharmacy compounding in the United States under FDA's 503A/503B bulk drug substance rules.
[8]